Trial Search Results

Autologous Stem Cell Rescue for Primary Amyloidosis

To evaluate the role of high dose therapy and autologous hematopoietic cell transplant for amyloidosis.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Intervention(s):

  • Procedure: high dose chemo then auto hematopoietic cell transplant

Phase:

Phase 2

Eligibility


Inclusion Criteria:1. Primary amyloidosis

2. Age < 75 years.

3. Patients must have their pathology reviewed and the diagnosis confirmed at Stanford
University Medical Center.

4. Patients who have undergone bone marrow transplantation previously will not be eligible.

5. Patients must have a Karnofsky performance status greater than 70%.

6. Patients must have a serum creatinine less than 2 mg/dl or creatinine clearance greater
than 30 ml/min, bilirubin less than 2 mg/dl, transaminases less than two times normal, left
ventricular ejection fraction >45% on echocardiography, cardiac index > 1.8 liters/min/m^2
and pulmonary function tests demonstrating FEV1 and DLCO > 60%.

7. Patients must be HIV negative.

8. Pregnant or lactating women will not be eligible to participate.

9. Patients must provide signed informed consent.

10. Patients with multiple myeloma and amyloid are eligible.

Exclusion Criteria:1. prior blood or marrow transplant

Ages Eligible for Study

18 Years - 75 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
BMT Referrals
6507230822
Not Recruiting